Metagenomi Therapeutics posts 2025 loss, pipeline gains
Metagenomi Therapeutics, Inc. reported full year 2025 results alongside key pipeline updates.
Rhea-AI Filing Summary
Metagenomi Therapeutics, Inc. reported full year 2025 results alongside key pipeline updates. The company ended December 31, 2025 with $160.8 million in cash, cash equivalents and marketable securities and expects this to fund operations through the fourth quarter of 2027.
Collaboration revenue was $25.2 million for 2025, while research and development expenses were $94.4 million and general and administrative expenses were $26.8 million. Net loss was $87.9 million, or $2.36 per basic and diluted share, on 37.3 million weighted average shares outstanding.
Operationally, the company completed a pre-IND meeting for its lead hemophilia A program MGX-001 after preclinical data in non-human primates showed curative FVIII activity, and it remains on track for a global regulatory submission, including an IND in the fourth quarter of 2026. It also reported in vivo proof-of-concept for Antithrombin (AT-III) Deficiency, advanced cardiometabolic collaborations with Ionis around APOC3, and completed a corporate name change to Metagenomi Therapeutics, Inc.
Positive
- Extended cash runway disclosed: Cash, cash equivalents and marketable securities of $160.8 million as of December 31, 2025 are anticipated to support operations through the fourth quarter of 2027, providing multi-year funding visibility for an early-stage pipeline.
- Lead program MGX-001 advancing toward clinic: Completed a pre-IND meeting after preclinical data showing curative FVIII activity in non-human primates and remains on track for a global regulatory submission, including an IND in the fourth quarter of 2026.
- Additional pipeline validation: Demonstrated in vivo proof-of-concept in non-human primates for Antithrombin (AT-III) Deficiency and highlighted APOC3 as a collaboration target with Ionis in significant cardiometabolic indications, broadening potential future indications.
Negative
- Collaboration revenue declined materially year over year: Collaboration revenue was $25.2 million for the full year 2025 compared to $52.3 million for 2024, indicating a substantial reduction in this revenue stream.
- Net loss increased despite lower operating expenses: Net loss widened to $87.9 million for 2025 from $78.1 million in 2024, even as research and development and general and administrative expenses decreased.
- Cash balance decreased over the year: Cash, cash equivalents and available-for-sale marketable securities were $160.8 million as of December 31, 2025 compared to $248.3 million as of December 31, 2024, reflecting significant cash usage during the period.
Insights
Pipeline milestones balance weaker revenue and a wider annual loss.
Metagenomi Therapeutics combined notable R&D progress with softer 2025 financial performance. Collaboration revenue was $25.2 million for the year ended December 31, 2025, down from $52.3 million, while the business highlighted multiple genome-editing programs moving toward the clinic.
Operating expenses declined as research and development fell to $94.4 million and general and administrative to $26.8 million, yet net loss still increased to $87.9 million. Cash, cash equivalents and marketable securities of $160.8 million support the stated runway through 4Q 2027, which is important for an early-stage platform company.
Scientifically, the pre-IND meeting and non-human primate data for MGX-001 in hemophilia A, plus proof-of-concept in Antithrombin (AT-III) Deficiency and APOC3 collaboration work with Ionis, help frame a clearer development path. Subsequent disclosures around the planned 4Q 2026 IND submission for MGX-001 and any new collaboration economics may further clarify long-term value.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Metagenomi Therapeutics (MGX) full year 2025 financial results?
How much cash does Metagenomi Therapeutics (MGX) have and what is its runway?
What progress did Metagenomi Therapeutics (MGX) report for its MGX-001 hemophilia A program?
Did Metagenomi Therapeutics (MGX) report any new proof-of-concept data in 2025?
How did Metagenomi Therapeutics (MGX) 2025 expenses compare to 2024?
What collaboration updates did Metagenomi Therapeutics (MGX) provide for cardiometabolic programs?
Did Metagenomi Therapeutics (MGX) change its corporate name in 2025?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On March 5, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
Earnings Press Release Issued by Metagenomi Therapeutics, Inc. on March 5, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Metagenomi Therapeutics, Inc. |
|
|
|
|
Date: |
March 5, 2026 |
By: |
/s/ Jian Irish |
|
|
|
Jian Irish, Ph.D., M.B.A. |
Exhibit 99.1
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026
Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company’s strategic evolution
$160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027
EMERYVILLE, Calif., MARCH 5, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the full year ended December 31, 2025, and provided business updates.
“2025 was a pivotal year for Metagenomi as we sharpened our strategic focus, advanced our core genome-editing technologies, and continued to demonstrate the breadth and durability of our technology across multiple therapeutic areas,” said Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company. “Over the year, we made meaningful progress across our pipeline and collaborations, which reinforce the versatility of our signature technologies and our ability to engineer differentiated genome-editing solutions tailored to specific disease contexts. With our corporate rebranding, we are entering 2026 with a clearer identity and mission centered on unlocking the full potential of precision genetic medicines.”
Fourth Quarter 2025 Updates
MGX-001 - Hemophilia A Program
Secreted Protein Deficiencies
Cardiometabolic Indications
Full Year 2025 Financial Results
Cash Position: Cash, cash equivalents, and available-for-sale marketable securities were $160.8 million as of December 31, 2025.
R&D Expenses: Research and development (R&D) expenses were $94.4 million for the full year ended December 31, 2025, compared to $109.2 million for the full year ended December 31, 2024.
G&A Expenses: General and administrative (G&A) expenses were $26.8 million for the full year ended December 31, 2025, compared to $32.0 million for the full year ended December 31, 2024.
About Metagenomi Therapeutics
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, integration and correction.
MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with best-in-class treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. The Company is also currently pursuing other secreted protein deficiencies leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward‐Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to conduct IND-enabling studies and make regulatory filings such as INDs, expectations regarding MGX-001 including the preclinical profile being potentially competitive with best-in-class treatment options and timing to submit the IND/CTA package, statements regarding the Company’s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones, statements concerning the potential of therapies and product candidates, statements concerning the impact of the organizational restructuring, statements concerning our anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contact:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
Condensed Financial Statements
Condensed Balance Sheet Data
(Unaudited)
|
|
December 31, |
|
|
December 31, |
|
||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Cash, cash equivalents and available-for-sale marketable securities |
|
$ |
160,799 |
|
|
$ |
248,307 |
|
Total assets |
|
$ |
221,103 |
|
|
$ |
324,599 |
|
Total liabilities |
|
$ |
62,507 |
|
|
$ |
89,742 |
|
Total stockholders’ equity |
|
$ |
158,596 |
|
|
$ |
234,857 |
|
Total liabilities and stockholders’ equity |
|
$ |
221,103 |
|
|
$ |
324,599 |
|
Condensed Statements of Operations
(Unaudited)
|
|
Years Ended December 31, |
|
|||||
(in thousands, except share and per share data) |
|
2025 |
|
|
2024 |
|
||
Collaboration revenue |
|
$ |
25,210 |
|
|
$ |
52,295 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
94,433 |
|
|
|
109,179 |
|
General and administrative |
|
|
26,790 |
|
|
|
32,017 |
|
Total operating expenses |
|
|
121,223 |
|
|
|
141,196 |
|
Loss from operations |
|
|
(96,013 |
) |
|
|
(88,901 |
) |
Other income (expense): |
|
|
|
|
|
|
||
Interest income |
|
|
9,470 |
|
|
|
14,722 |
|
Change in fair value of long-term investments |
|
|
(1,292 |
) |
|
|
(9,185 |
) |
Other expense, net |
|
|
(91 |
) |
|
|
(207 |
) |
Total other income, net |
|
|
8,087 |
|
|
|
5,330 |
|
Net loss before benefit from income taxes |
|
|
(87,926 |
) |
|
|
(83,571 |
) |
Benefit from income taxes |
|
|
58 |
|
|
|
5,513 |
|
Net loss |
|
$ |
(87,868 |
) |
|
$ |
(78,058 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(2.36 |
) |
|
$ |
(2.36 |
) |
Weighted average common shares outstanding, basic and diluted |
|
|
37,251,050 |
|
|
|
33,027,889 |
|